Forecasts by Type (mRNA Prophylactic Vaccines, Therapeutics Vaccines, mRNA Therapeutics), by Vector (Self-amplifying, Non-amplifying mRNA), by Vector Platforms (naked mRNA, Cell-Specific, Carrier Mediated), by Carrier Mediated (Viral, Non-viral), by Non-viral (Polymer-based Vectors, Lipid Nanoparticles, Peptide-based Vectors), by Route of Delivery (Intradermal, Subcutaneous, Intramuscular, Intravenous, Intranodal), by Applications (Cell Therapy, Gene Editing, Protein Replacement, Cancer Immunotherapy, Infectious Diseases), by End-users (Hospitals & Clinics, Research Organizations) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
The mRNA Vaccines & Therapeutics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
CDMOs Seizing Opportunities in the Newly Commercializing mRNA Market A successful application of mRNA technology for COVID-19 has reinvigorated biopharmaceutical companies to further explore opportunities of this technology for other diseases. There has been a significant increase in therapeutic mRNA programs that are focused on mRNA and its delivery platform, which is the major challenge for the delivery of mRNA into the cells. The Contract Development and Manufacturing Organisations (CDMOs) have also been compelled to ramp in their production capabilities to meet this surge in demand. Many existing CDMOs have made huge capital investments through developing and upgrading their manufacturing capabilities and processes to match GMP standards for vaccine development. These companies are making strategic partnerships and acquisitions to fortify their mRNA manufacturing technologies. For instance, Korea-based Samsung Biologics had signed an agreement with Moderna in May 2021 for aseptic fill-finish and packaging and labeling of Moderna’s COVID-19 mRNA vaccine. In August 2021 Samsung Biologics announced its plan in three areas which included capacity expansion setting up an R&D center in the U.S. for support of its clients at a global scale, and expansion of the platform to support diverse applications.
What Questions Should You Ask before Buying a Market Research Report? • How is the mRNA vaccines & therapeutics market evolving? • What is driving and restraining the mRNA vaccines & therapeutics market? • How will each mRNA vaccines & therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032? • How will the market shares for each mRNA vaccines & therapeutics submarket develop from 2022 to 2032? • What will be the main driver for the overall market from 2022 to 2032? • Will leading mRNA vaccines & therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032? • Who are the leading players and what are their prospects over the forecast period? • What are the mRNA vaccines & therapeutics projects for these leading companies? • How will the industry evolve during the period between 2022 and 2032? What are the implications of mRNA vaccines & therapeutics projects taking place now and over the next 10 years? • Is there a greater need for product commercialisation to further scale the mRNA Vaccines & Therapeutics market? • Where is the mRNA vaccines & therapeutics market heading and how can you ensure you are at the forefront of the market? • What are the best investment options for new product and service lines? • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the mRNA Vaccines & Therapeutics market today, and over the next 10 years: • Our 411-page report provides 164 tables and 242 charts/graphs exclusively to you. • The report highlights key lucrative areas in the industry so you can target them – NOW. • It contains in-depth analysis of global, regional and national sales and growth. • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the mRNA Vaccines & Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
The report delivers exclusive COVID-19 variations and economic data specific to your market.
Forecasts to 2032 and other analyses reveal commercial prospects • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares. • You will find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising mRNA Vaccines & Therapeutics recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
mRNA Vaccines & Therapeutics Market by Route of Administration • Intramuscular • Intravenous • Intradermal • Subcutaneous • Intranodal
mRNA Vaccines & Therapeutics Market by Application • Cell Therapy • Protein Replacement Therapy • Gene Editing • Cancer Immunotherapy • Infectious Diseases (including COVID-19)
mRNA Vaccines & Therapeutics Market by End-Users • Hospitals & Clinics • Research Organizations
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America • U.S. • Canada
Europe • Germany • UK • France • Italy • Spain • Rest of Europe
Asia Pacific • China • Japan • India • Australia • South Korea • Rest of Asia Pacific
Latin America • Brazil • Mexico • Argentina • Rest of Latin America
The report also includes profiles and for some of the leading companies in the mRNA Vaccines & Therapeutics Market Report 2022-2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth • AstraZeneca PLC • Moderna • CureVac N.V. • BioNTech SE • Pfizer Inc., • GSK PLC • Arcturus Therapeutics Holding Inc. • Translate Bio (now a Sanofi Company) • Sanofi • eTheRNA • Stemirna Therapeutics • Cartesian Therapeutics • Ethris
Overall world revenue for mRNA Vaccines & Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$64,338 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the mRNA Vaccines & Therapeutics Market, 2022 to 2032 report help you? In summary, our 410+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for mRNA Vaccines & Therapeutics Market, 2022 to 2032 Market, with forecasts for services, company size, drug type, and therapeutic area each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for four regional and 22 key national markets – See forecasts for the mRNA Vaccines & Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the mRNA Vaccines & Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the mRNA Vaccines & Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Buy our report today mRNA Vaccines & Therapeutics Market Report 2022-2032: Forecasts by Type (mRNA Prophylactic Vaccines, Therapeutics Vaccines, mRNA Therapeutics), by Vector (Self-amplifying, Non-amplifying mRNA), by Vector Platforms (naked mRNA, Cell-Specific, Carrier Mediated), by Carrier Mediated (Viral, Non-viral), by Non-viral (Polymer-based Vectors, Lipid Nanoparticles, Peptide-based Vectors), by Route of Delivery (Intradermal, Subcutaneous, Intramuscular, Intravenous, Intranodal), by Applications (Cell Therapy, Gene Editing, Protein Replacement, Cancer Immunotherapy, Infectious Diseases), by End-users (Hospitals & Clinics, Research Organizations) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview 1.1 Objectives of the Study 1.2 Introduction to mRNA Vaccines & Therapeutics Market 1.3 What This Report Delivers 1.4 Why You Should Read This Report 1.5 Key Questions Answered By This Analytical Report Include: 1.6 Who is This Report For? 1.7 Methodology 1.7.1 Market Definitions 1.7.2 Market Evaluation & Forecasting Methodology 1.7.3 Data Validation 1.7.3.1 Primary Research 1.7.3.2 Secondary Research 1.8 Frequently Asked Questions (FAQs) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2 Executive Summary
3 Market Overview 3.1 Key Findings 3.2 Market Dynamics 3.2.1 Market Driving Factors 3.2.1.1 Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success 3.2.1.2 Significant Research Funding to Boost Market Growth 3.2.1.3 Technological Advances Driving the Market Growth 3.2.2 Market Restraining Factors 3.2.2.1 Scalability and Cost-Effectiveness is Still a Major Bottleneck 3.2.3 Market Opportunities 3.2.3.1 mRNA Cancer Vaccines 3.2.3.2 Analytics, Machine Learning and Cloud Data Warehousing 3.3 COVID-19 Impact Analysis 3.4 Porter’s Five Forces Analysis 3.4.1 Bargaining Power of Suppliers 3.4.2 Bargaining Power of Buyers 3.4.3 Competitive Rivalry 3.4.4 Threat of Substitutes 3.4.5 Threat of New Entrants 3.5 PEST Analysis 3.5.1 Political Factors 3.5.2 Economic Factors 3.5.3 Social Factors 3.5.4 Technological Factors
4 Global mRNA vaccines & therapeutics Market, By Type 4.1 Key Findings 4.2 Type Segment Growth Prospects 4.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Type 4.4 Prophylactic vaccines 4.4.1 Market Size by Region, 2022-2032 (US$ Mn) 4.4.2 Market Share by Region, 2022-2032 (%) 4.5 Therapeutic Vaccines Market 4.5.1 Therapeutics Vaccines Market Forecast by Region, 2022-2032 (US$ Mn) 4.5.2 Therapeutic Vaccine Forecast by Region, 2022-2032 (%) 4.6 mRNA Therapeutics Market Forecast 4.6.1 mRNA Therapeutics Market Forecast by Region 2022-2032 (US$ Mn) 4.6.2 mRNA Therapeutics Market by Region, 2022-2032 (%)
5 mRNA Vaccines & Therapeutics Market Analysis by Applications 5.1 Key Findings 5.2 Applications Segment Growth Prospects 5.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Applications 5.4 mRNA vaccines & therapeutics Market Share by Applications, 2022 & 2032 5.5 Cell Therapy 5.5.1 Cell Therapy Market Forecast by Region, 2022-2032 (US$ Mn) 5.5.2 Cell Therapy Market Share by Region, 2022-2032 (%) 5.6 Gene Editing 5.6.1 Gene Editing Market Forecast by Region, 2022-2032 (US$ Mn) 5.6.2 Gene Editing Market Share by Region, 2022-2032 (%) 5.7 Protein Replacement Therapy 5.7.1 Protein Replacement Market Forecast by Region, 2022-2032 (US$ Mn) 5.7.2 Protein Replacement Market Share by Region, 2022-2032 (%) 5.8 Cancer Immunotherapy 5.8.1 Cancer Immunotherapy Market Forecast by Region, 2022-2032 (US$ Mn) 5.8.2 Cancer Immunotherapy Market Share by Region, 2022-2032 (%) 5.9 Infectious Diseases 5.9.1 Infectious Diseases Market Forecast by Region, 2022-2032 (US$ Mn) 5.9.2 mRNA Infectious Diseases Application Market Share by Region, 2022-2032 (%)
6 mRNA Vaccine & Therapeutics Market, By Vector Platform 6.1 Key Findings 6.2 Vector Platform Segment Growth Prospects 6.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Vector Platform 6.4 Global mRNA vaccines & therapeutics Market Share by Vector Platforms, 2022 & 2032 6.5 Self-Amplifying mRNA 6.5.1 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn) 6.5.2 Self-Amplifying mRNA Market Share by Region, 2022-2032 (%) 6.6 Non-Amplifying (Conventional) mRNA 6.6.1 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn) 6.6.2 Non-Amplifying mRNA Market Share by Region, 2022-2032 (%)
7 Global mRNA Vaccines & Therapeutics Market, By Delivery Mode 7.1 Key Findings 7.2 Delivery Platform Segment Growth Prospects 7.3 Global mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Delivery Platform, 2022 & 2032 7.4 Naked mRNA Delivery 7.4.1 Naked Delivery Platform Forecast by Region, 2022-2032 (US$ Mn) 7.4.2 Naked Delivery Platform Market Share by Region, 2022-2032 (%) 7.5 Cell-Specific Delivery Platform 7.5.1 Cell Specific Delivery Platform by Region, 2022-2032 (US$ Mn) 7.5.2 Cell Specific Delivery Platform Market Share by Region, 2022-2032 (%) 7.6 Carrier Mediated 7.6.1 Carrier Mediated Delivery Platform Market by Region, 2022-2032 (US$ Mn) 7.6.2 Carrier Mediated Platform Market Share by Region, 2022-2032 (%) 7.6.3 Carrier Mediated Delivery Platform Market by Types, 2022-2032 (US$ Mn) 7.6.3.1 Viral Vector 7.6.3.1.1.1 Viral Vector Market by Region, 2022-2032 (US$ Mn) 7.6.3.1.1.2 Viral Vector Market Share by Region, 2022-2032 (%) 7.6.3.2 Non-Viral 7.6.3.2.1 Non-Viral Market by Region, 2022-2032 (US$ Mn) 7.6.3.2.2 Non-Viral Market Share by Region, 2022-2032 (%) 7.6.3.3 Non-Viral Vector Market by Types, 2022-2032 (US$ Mn) 7.6.3.3.1.1 Lipid Nanoparticles (LNP) 7.6.3.3.1.2 Peptide-based Vectors 7.6.3.3.1.3 Polymer-based Vectors
8 Global mRNA Vaccines & Therapeutics Market, By Route of Delivery 8.1 Key Findings 8.2 Route of Delivery Segment Growth Prospects 8.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast, by Route of Delivery, 2022 & 2032 8.4 Intradermal 8.4.1 Intradermal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn) 8.4.2 Intradermal Route of Delivery Forecast by Region, 2022-2032 (%) 8.5 Subcutaneous 8.5.1 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn) 8.5.2 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (%) 8.6 Intramuscular 8.6.1 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (US$ Mn) 8.6.2 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (%) 8.7 Intravenous 8.7.1 Intravenous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn) 8.7.2 Intravenous Route of Delivery Forecast by Region, 2022-2032 (%) 8.8 Intranodal 8.8.1 Intranodal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn) 8.8.2 mRNA Intranodal Route of Delivery Forecast by Region, 2022-2032 (%)
9 Global mRNA Based Therapeutics and Vaccine Market by End-User 9.1 Key Findings 9.2 End Users Segment Growth Prospects 9.3 Global mRNA vaccines & therapeutics Market Size Estimation, by End Users, 2022 & 2032 9.4 Research Organizations 9.4.1 Research Organizations Market Forecast, By End Users, by Region, 2022-2032 (US$ Mn) 9.4.2 Research Organizations Market Share by Region, 2022-2032 (%) 9.5 Hospitals & Clinics Segment Market Forecast, 2022-2032 9.5.1 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn) 9.5.2 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (%)`
10 Global mRNA vaccines & therapeutics Market Analysis by Region 10.1 Key Findings 10.2 Regional Market Size Estimation and Forecast 10.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
11 North America mRNA Vaccines & Therapeutics Market Analysis 11.1 Key Findings 11.2 North America mRNA Vaccines & Therapeutics Market Attractiveness Index 11.3 North America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn) 11.4 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 11.5 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types 11.6 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform 11.7 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform 11.7.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform 11.7.1.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform 11.8 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications 11.9 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery 11.10 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users 11.11 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country 11.11.1 U.S. 11.11.2 Canada
12 Europe mRNA Vaccines & Therapeutics Market Analysis 12.1 Key Findings 12.2 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index 12.3 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn) 12.4 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 12.5 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types 12.6 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform 12.7 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform 12.7.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Vector Delivery Platform 12.7.1.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform 12.8 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications 12.9 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery 12.10 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users 12.11 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country 12.11.1 Germany 12.11.2 U.K. 12.11.3 France 12.11.4 Spain 12.11.5 Italy 12.11.6 Rest of Europe
13 Asia Pacific mRNA Vaccines & Therapeutics Market Analysis 13.1 Key Findings 13.2 Asia Pacific mRNA Vaccines & Therapeutics Market Attractiveness Index 13.3 Asia Pacific mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn) 13.4 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 13.5 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types 13.6 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform 13.7 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform 13.7.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform 13.7.1.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform 13.8 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications 13.9 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery 13.10 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users 13.11 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 13.11.1 China 13.11.2 India 13.11.3 Japan 13.11.4 South Korea 13.11.5 Australia 13.11.6 Rest of Asia Pacific
14 Latin America mRNA Vaccines & Therapeutics Market Analysis 14.1 Key Findings 14.2 Latin America mRNA Vaccines & Therapeutics Market Attractiveness Index 14.3 Latin America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn) 14.4 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 14.5 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types 14.6 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform 14.7 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform 14.7.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform 14.7.1.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform 14.8 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications 14.9 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery 14.10 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users 14.10.1 Brazil 14.10.2 Argentina 14.10.3 Mexico 14.10.4 Rest of Latin America
15 Middle East & Africa mRNA Vaccine & Therapeutics Market Analysis 15.1 Key Findings 15.2 Middle East & Africa mRNA Vaccines & Therapeutics Market Attractiveness Index 15.3 Middle East & Africa mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn) 15.4 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country 15.5 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types 15.6 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform 15.7 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform 15.7.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform 15.7.1.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform 15.8 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications 15.9 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery 15.10 Middle East & Africa mRNA vaccines & therapeutics Market Size Estimation and Forecast, by End-Users 15.10.1 Saudi Arabia 15.10.2 UAE 15.10.3 Turkey 15.10.4 South Africa 15.10.5 Rest of Middle East & Africa
16 Company Profiles 16.1 Company Share Analysis 16.2 Key Business Strategy Analysis 16.3 AstraZeneca PLC 16.3.1 Company Snapshot 16.3.2 Company Overview 16.3.3 Financial Analysis 16.3.3.1 Net Revenue, 2017-2021 16.3.3.2 Core Operating Profit, 2017-2021 16.3.3.3 R&D, 2017-2021 16.3.3.4 Regional Pharmaceutical Market Revenue, 2017-2021 16.3.4 AstraZeneca: COVID Vaccine Sales, 2021 16.3.5 AstraZeneca PLC: Development Pipeline 16.3.6 Strategic Outlook 16.4 Moderna 16.4.1 Company Snapshot 16.4.2 Company Overview 16.4.3 Financial Analysis 16.4.3.1 Net Revenue, 2017-2021 16.4.3.2 R&D Expense, 2017-2021 16.4.3.3 Regional Pharmaceutical Market Shares, 2021 16.4.4 Moderna: Vaccines & Therapeutics Development Pipeline 16.4.5 Strategic Outlook 16.5 CureVac N.V. 16.5.1 Company Snapshot 16.5.2 Company Overview 16.5.3 Financial Analysis 16.5.3.1 Net Revenue, 2018-2021 16.5.3.2 CureVac N.V. Revenues from Contract Customers: 2018-2021 16.5.3.3 R&D Expense, 2018-2021 16.5.3.4 Regional Pharmaceutical Market Shares (%), 2018-2021 16.5.4 CureVac N.V.: Vaccines & Therapeutics Development Pipeline 16.5.5 Strategic Outlook 16.6 BioNTech SE 16.6.1 Company Snapshot 16.6.2 Company Overview 16.6.3 Financial Analysis 16.6.3.1 Net Revenue, 2018-2021 16.6.3.2 BioNTech SE Revenues from R&D Collaborations: 2018-2021 16.6.3.3 R&D Expense, 2018-2021 16.6.3.4 Regional Revenues by Collaborations (US$ Million), 2018-2021 16.6.4 BioNTech SE: Vaccines & Therapeutics Development Pipeline 16.6.5 Strategic Outlook 16.7 Pfizer Inc. 16.7.1 Company Snapshot 16.7.2 Company Overview 16.7.3 Financial Analysis 16.7.3.1 Net Revenue, 2017-2021 16.7.3.2 Net Income: 2017-2021 16.7.4 Pfizer Inc.: mRNA Vaccine Approval Status 16.7.5 Strategic Outlook 16.8 GSK Plc. 16.8.1 Company Snapshot 16.8.2 Company Overview 16.8.3 Financial Analysis 16.8.3.1 Net Revenue, 2017-2021 16.8.3.2 R&D Expense: 2017-2021 16.8.3.3 Geographic Revenues, By Segment, 2019-2021 16.8.3.4 Regional Revenues (US$ Million), 2018-2021 16.8.4 GSK Inc.: mRNA Vaccine Pipeline Status 16.8.5 Strategic Outlook 16.9 Arcturus Therapeutics Holdings Inc. 16.9.1 Company Snapshot 16.9.2 Company Overview 16.9.3 Financial Analysis 16.9.3.1 Net Revenue, 2019-2021 16.9.3.2 Arcturus Therapeutics Holdings Inc., Collaboration Revenues (2019-2021) 16.9.4 Arcturus Therapeutics Holdings Inc: mRNA Vaccine Pipeline Status 16.9.5 Strategic Outlook 16.10 Translate Bio ( now A Sanofi Company) 16.10.1 Company Snapshot 16.10.2 Company Overview 16.10.3 Financial Analysis 16.10.3.1 Net Revenue, 2018-2020 16.10.3.2 R&D Expense (US$ Million), 2018-2020 16.10.4 Translate Bio (a Sanofi Company): mRNA Vaccine Pipeline Status 16.10.5 Strategic Outlook 16.11 Sanofi 16.11.1 Company Snapshot 16.11.2 Company Overview 16.11.3 Financial Analysis 16.11.3.1 Net Revenue, 2017-2021 16.11.3.2 R&D Expense (US$ Million), 2017-2021 16.11.3.3 Sanofi, Net Income (2017-2021) 16.11.4 Sanofi Company: mRNA Vaccine Pipeline Status 16.11.5 Strategic Outlook 16.12 eTheRNA 16.12.1 Company Snapshot 16.12.2 Company Overview 16.12.3 Partnerships/ Strategic Collaborations 16.12.4 Strategic Outlook 16.13 Stemirna Therapeutics 16.13.1 Company Snapshot 16.13.2 Company Overview 16.13.3 Stemirna: mRNA Vaccine Pipeline Status 16.14 Cartesian Therapeutics 16.14.1 Company Snapshot 16.14.2 Company Overview 16.14.3 Cartesian: mRNA Vaccine Pipeline Status 16.14.4 Strategic Outlook 16.15 Ethris 16.15.1 Company Snapshot 16.15.2 Company Overview 16.15.3 Ethris: mRNA Vaccine Pipeline Status 16.15.4 Strategic Outlook
17 Conclusion and Recommendations 17.1 Concluding Remarks from Visiongain 17.2 Recommendations for Market Players
List of Tables Table 1 Global mRNA Vaccines & Therapeutics Market Snapshot, 2022 & 2032 (US$ million, CAGR %) Table 2 Global mRNA vaccines & therapeutics market : Phase III Table 3 Global mRNA vaccines & therapeutics market : Companies & Delivery Platforms Table 4 Global mRNA vaccines & therapeutics Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario Table 5 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario Table 6 Global mRNA vaccines & Therapeutic Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario Table 7 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario Table 8 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 9 Prophylactic Vaccine in Pipeline Analysis Table 10 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 11 mRNA Cancer Vaccine in Pipeline Analysis Table 12 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %) Table 13 mRNA Cancer Vaccine in Pipeline Analysis Table 14 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 15 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %) Table 16 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 17 mRNA vaccines & Therapeutics, Gene Editing Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 18 Clinical Trials of mRNA for Protein-Replacement Therapies Table 19 mRNA vaccines & Therapeutics, Protein Replacement Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 20 Clinical Trials of mRNA for Cancer vaccines and Therapeutic Table 21 mRNA vaccines & Therapeutics, Cancer Immunotherapy Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 22 Clinical Trials of mRNA for Infectious Diseases Table 23 mRNA vaccines & Therapeutics, Infectious Diseases Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 24 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 25 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%) Table 26 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %) Table 27 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 28 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 29 mRNA Therapeutic & Vaccine Forecast by Cell Specific Delivery Table 30 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 31 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 32 Carrier Mediated Delivery Platform Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 33 Viral Vector Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 34 Non- Viral Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 35 Non-Viral Vector Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 36 mRNA delivery by Lipid Nanoparticle Platform Clinical trials Table 37 Lipid Nano Particles Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 38 Global Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 39 Global Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 40 Global mRNA Therapeutic and Vaccine Delivery, By Route of Administration Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 41 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR %) Table 42 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 43 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 44 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 45 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 46 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 47 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR%, CAGR %) Table 48 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 49 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Table 50 Global mRNA Vaccines & Therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)) Table 51 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario Table 52 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario Table 53 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario Table 54 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario Table 55 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 56 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %) Table 57 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 58 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 59 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 60 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 61 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %) Table 62 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%) Table 63 North America mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%) Table 64 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 65 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 66 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 67 .Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %) Table 68 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 69 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 70 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 71 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 72 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%) Table 73 Europe mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%) Table 74 Europe mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR %) Table 75 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 76 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 77 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 78 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 79 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 80 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 81 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 82 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %) Table 83 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 84 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 85 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 86 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 87 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %) Table 88 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%) Table 89 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%) Table 90 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 91 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 92 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 93 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 94 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 95 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 96 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 97 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %) Table 98 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 99 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 100 .Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 101 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 102 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%) Table 103 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%) Table 104 Latin America mRNA Vaccines & Therapeutics market Forecast by End Users-2032 (US$ million, AGR%, CAGR %) Table 105 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 106 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 107 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 108 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 109 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 110 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %) Table 111 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 112 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 113 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%) Table 114 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %) Table 115 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%) Table 116 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%) Table 117 Middle East & Africa mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%) Table 118 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 119 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 120 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 121 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 122 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 123 Key Business Strategies Adopted by Key Players in Global MRNA vaccines & therapeutics market Table 124 AstraZeneca PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 125 AstraZeneca PLC: Pipeline Development Table 126 AstraZeneca PLC : Strategic Outlook Table 127 Moderna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 128 Moderna : mRNA Therapeutics & vaccines Pipeline 2022-2032 Table 129 Moderna : Strategic Outlook Table 130 CureVac N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 131 CureVac N.V., Revenues from Contract Customers,2018-2021 (US$ million, AGR %) Table 132 CureVac N.V.: mRNA Therapeutics & Vaccines Pipeline 2022-2032 Table 133 CureVac N.V.: Strategic Outlook Table 134 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 135 BioNTech SE, Revenues from R&D Collaborations,2018-2021 (US$ million) Table 136 BioNTech SE: mRNA Therapeutics & Vaccines Pipeline 2022-2032 Table 137 BioNTech SE: Strategic Outlook Table 138 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 139 Pfizer Inc.: mRNA Vaccine Approval Status Table 140 Pfizer Inc.: Strategic Outlook Table 141 GSK Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 142 GSK Plc: Revenues, By Segment, 2019-2021 (US$ million, AGR %) Table 143 GSK Plc: Regional Revenues, 2018-2021 (US$ million) Table 144 GSK Plc: mRNA Vaccine Approval Status Table 145 GSK Plc: Strategic Outlook Table 146 Arcturus Therapeutics Holdings Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 147 Arcturus Therapeutics Holdings Inc.: mRNA Vaccine and Therapeutics Pipeline Table 148 Arcturus Therapeutics Holdings Inc.: Strategic Outlook Table 149 Translate Bio ( A Sanofi Company).: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 150 Translate Bio ( A Sanofi Company).: mRNA Vaccine and Therapeutics Pipeline Table 151 Translate Bio ( A Sanofi Company).: Strategic Outlook Table 152 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 153 Sanofi: mRNA Vaccine and Therapeutics Pipeline Table 154 Sanofi: Strategic Outlook Table 155 eTheRNA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 156 ETheRNA: mRNA Strategic Collaborations Table 157 ETheRNA: Strategic Outlook Table 158 Stemirna Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 159 Stemirna Therapeutics: mRNA Strategic Collaborations Table 160 Cartesian Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 161 Cartesian Therapeutics: mRNA Strategic Collaborations Table 162 Cartesian : Strategic Outlook Table 163 Ethris: mRNA Pipeline Table 164 Ethris: Strategic Outlook
List of Figures Figure 1 Global mRNA Vaccines & Therapeutics Market Segmentation Figure 2 Global mRNA vaccines & therapeutics Market Forecast by Region: Market Attractiveness Index Figure 3 Global mRNA vaccines & therapeutics Market by Therapeutics: Market Attractiveness Index Figure 4 Global mRNA vaccines & therapeutics Market by Vector Platform: Market Attractiveness Index Figure 5 Global mRNA vaccines & therapeutics Market by Delivery Platform: Market Attractiveness Index Figure 6 Global mRNA vaccines & therapeutics Market by Route of Administration: Market Attractiveness Index Figure 7 Global mRNA vaccines & therapeutics Market by Applications: Market Attractiveness Index Figure 8 Global mRNA vaccines & therapeutics market by End Users : Market Attractiveness Index Figure 9 Global mRNA vaccines & therapeutics market Dynamics Figure 10 Global COVID Impact Analysis: mRNA vaccines & therapeutics Market Recovery Scenarios (US$ million, CAGR %) Figure 11 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery Figure 12 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery Figure 13 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery Figure 14 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery Figure 15 Global mRNA vaccines & therapeutics Market: Porter’s Five Forces Analysis Figure 16 Global mRNA vaccines & therapeutics Market: PEST Analysis Figure 17 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Type Figure 18 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 19 Global mRNA vaccines & therapeutics Market Share Forecast by Type, 2022, 2032 (%) Figure 20 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn) Figure 21 Prophylactic vaccines Market Forecast by Region, 2022-2032 (%) Figure 22 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million) Figure 23 Therapeutic Vaccine Forecast by Region, 2022-2032 (%) Figure 24 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million) Figure 25 mRNA Therapeutics Market Forecast by Region, 2022-2032 (%) Figure 26 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Applications Figure 27 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 28 mRNA vaccines & therapeutics Market Share Forecast by Applications, 2022, 2032 (%) Figure 29 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million) Figure 30 Cell Therapy Market Share by Region, 2022-2032 (%) Figure 31 mRNA Vaccine & Therapeutics, By Gene Editing Forecast by Region, 2022-2032 (US$ million) Figure 32 mRNA Gene Editing Application Market, Forecast by Region, 2022-2032 (%) Figure 33 mRNA Vaccine & Therapeutics, By Protein Replacement Forecast by Region, 2022-2032 (US$ million) Figure 34 mRNA Protein Replacement Application Market, Forecast by Region, 2022-2032 (%) Figure 35 mRNA Vaccine & Therapeutics, By Cancer Immunotherapy Forecast by Region, 2022-2032 (US$ million) Figure 36 mRNA Cancer Immunotherapy Application Market, Forecast by Region, 2022-2032 (%) Figure 37 mRNA Vaccine & Therapeutics, By Infectious Diseases Forecast by Region, 2022-2032 (US$ million) Figure 38 mRNA Infectious Diseases Application Market, Forecast by Region, 2022-2032 (%) Figure 39 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Vector Platform Figure 40 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 41 Global mRNA vaccines & therapeutics Market Share Forecast by Vector Platform, 2022, 2032 (%) Figure 42 Self-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million) Figure 43 Self-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%) Figure 44 Non-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million) Figure 45 Non-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%) Figure 46 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Delivery Platform Figure 47 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 48 Global mRNA vaccines & therapeutics Market Share Forecast by Delivery Platform, 2022, 2032 (%) Figure 49 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 50 Naked Delivery Platform Market Forecast by Region, 2022-2032(%) Figure 51 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million) Figure 52 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 53 Carrier Mediated Platform Market Forecast by Region, 2022-2032 (US$ million) Figure 54 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 55 Viral Vector Market Forecast by Region, 2022-2032 (US$ million) Figure 56 Viral Vector Market Share Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 57 Non-Viral Market Forecast by Region, 2022-2032 (US$ million) Figure 58 Non-Viral Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 59 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million) Figure 60 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 61 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million) Figure 62 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 63 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million) Figure 64 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%) Figure 65 Global mRNA Vaccines & Therapeutics Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR %) Figure 66 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 67 Global mRNA vaccines & therapeutics Market Share Forecast by Route of Delivery, 2022, 2032 (%) Figure 68 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 69 Intradermal Route of Delivery Market Forecast by Region, 2022-2032(%) Figure 70 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 71 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032(%) Figure 72 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 73 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032(%) Figure 74 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 75 Intravenous Route of Delivery Market Forecast by Region, 2022-2032(%) Figure 76 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %) Figure 77 Global mRNA Intranodal Route of Delivery Market Forecast by Region, 2022-2032(%) Figure 78 Global mRNA vaccines & therapeutics Market Forecast by End-Users 2022, 2027, 2032 (Revenue, CAGR %) Figure 79 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR %) Figure 80 Global mRNA vaccines & therapeutics Market Share Forecast by End Users, 2022, 2032 (%) Figure 81 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn ) Figure 82 Research Organizations Market Share Forecast, by Region, 2022-2032(%) Figure 83 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (US$ Mn ) Figure 84 Hospitals & Clinics Market Forecast, by Region, 2022-2032(%) Figure 85 Global mRNA Vaccines & Therapeutics Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%) Figure 86 Global mRNA Vaccines & Therapeutics Market Share Forecast by Region 2022, 2027, 2032(%) Figure 87 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)) Figure 88 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery Figure 89 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery Figure 90 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery Figure 91 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery Figure 92 North America mRNA Vaccines & Therapeutics Market Attractiveness Index Figure 93 North America mRNA Vaccines & Therapeutics market by Region, 2022, 2027 & 2032 (US$ million) Figure 94 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 95 North America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%) Figure 96 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %) Figure 97 North America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%) Figure 98 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 99 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%) Figure 100 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 101 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%) Figure 102 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 103 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%) Figure 104 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 105 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%) Figure 106 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 107 North America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%) Figure 108 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 109 North America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%) Figure 110 North America mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR %) Figure 111 North America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%) Figure 112 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 113 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 114 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index,2022 Figure 115 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ million) Figure 116 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 117 Europe mRNA vaccines & therapeutics Market Share Forecast by Country, 2022 & 2032 (%) Figure 118 Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %) Figure 119 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%) Figure 120 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 121 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%) Figure 122 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 123 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%) Figure 124 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 125 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%) Figure 126 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 127 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%) Figure 128 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 129 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%) Figure 130 Europe mRNA Vaccines & Therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 131 Europe mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%) Figure 132 Europe mRNA Vaccines & Therapeutics Market Forecast by End Users-2032 (US$ million, AGR %) Figure 133 Europe mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%) Figure 134 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 135 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 136 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 137 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 138 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 139 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 140 Asia Pacific mRNA vaccines and Therapeutics Market Attractiveness Index Figure 141 Asia Pacific mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million) Figure 142 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 143 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%) Figure 144 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %) Figure 145 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%) Figure 146 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 147 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%) Figure 148 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 149 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%) Figure 150 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 151 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%) Figure 152 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 153 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%) Figure 154 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 155 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%) Figure 156 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 157 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%) Figure 158 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR %) Figure 159 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%) Figure 160 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 161 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 162 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 163 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 164 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 165 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 166 Latin America mRNA vaccines and Therapeutics Market Attractiveness Index Figure 167 Latin America mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million) Figure 168 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 169 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%) Figure 170 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %) Figure 171 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%) Figure 172 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 173 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%) Figure 174 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 175 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%) Figure 176 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 177 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%) Figure 178 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 179 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%) Figure 180 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 181 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%) Figure 182 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 183 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%) Figure 184 Latin America mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %) Figure 185 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%) Figure 186 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 187 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 188 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 189 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 190 Middle East & Africa mRNA vaccines and Therapeutics Market Attractiveness Index Figure 191 Middle East & Africa mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million) Figure 192 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 193 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%) Figure 194 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %) Figure 195 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%) Figure 196 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %) Figure 197 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%) Figure 198 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 199 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%) Figure 200 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 201 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%) Figure 202 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %) Figure 203 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%) Figure 204 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %) Figure 205 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%) Figure 206 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %) Figure 207 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%) Figure 208 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %) Figure 209 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%) Figure 210 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 211 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 212 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 213 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 214 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %) Figure 215 Global mRNA vaccines & therapeutics market: Company Share Analysis, 2021 Figure 216 AstraZeneca PLC: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 217 AstraZeneca PLC Holdings AG: Core Operating Profit, 2017-2021 (US$ million, AGR%) Figure 218 AstraZeneca PLC: R&D, 2017-2021 (US$ million, AGR%) Figure 219 AstraZeneca PLC: Regional Pharmaceutical Revenues, By Region 2017-2021 (US$ million) Figure 220 AstraZeneca PLC: Revenues, By Disease Area, 2021 (% share) Figure 221 Moderna: Net Revenue, 2017-2021 (US$ million, AGR%) Figure 222 Moderna, Revenues By Collaboration 2017-2021 (US$ million) Figure 223 Moderna: R&D Expense, 2017-2021 (US$ million, AGR%) Figure 224 Moderna: Regional Pharmaceutical Market Shares, 2021 (%) Figure 225 CureVac N.V.: Net Revenue, 2018-2021 (US$ million, AGR %) Figure 226 CureVac N.V.: R&D Expense, 2018-2021 (US$ million, AGR %) Figure 227 CureVac N.V.: Regional Pharmaceutical Market Shares, 2018-2021 (%) Figure 228 BioNTech SE: Net Revenue, 2018-2021 (US$ million, AGR %) Figure 229 BioNTech SE: R&D Expense, 2018-2021 (US$ million, AGR %) Figure 230 BioNTech SE: Regional Revenues by Collaborations, 2018-2021 (US$ million) Figure 231 Pfizer Inc: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 232 Pfizer Inc. Net Income: 2017-2021 (US$ million, AGR %) Figure 233 GSK Plc,: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 234 GSK Plc. R&D Expense: 2017-2021 (US$ million, AGR %) Figure 235 Arcturus Therapeutics Holdings Inc., Net Revenues=, 2019-2021 (US$ million, AGR %) Figure 236 Arcturus Therapeutics Holdings Inc.: Collaboration Revenues, 2019-2021 (US$ million) Figure 237 Translate Bio (A Sanofi Company), Net Revenues from Collaborations 2018-2020 (US$ million, AGR %) Figure 238 Translate Bio ( A Sanofi Company).: R&D Expense, 2018-2020 (US$ million) Figure 239 Sanofi, Net Revenue, 2017-2021 (US$ million, AGR %) Figure 240 Sanofi: R&D Expense, 2017-2021 (US$ million) Figure 241 Sanofi: Net Income, 2017-2021 (US$ million) Figure 242 Sanofi: Business Segments Revenue, 2018-2021 (US$ million)
List of Companies Profiled in the report Arcturus Therapeutics Holding Inc. AstraZeneca PLC BioNTech SE Cartesian Therapeutics CureVac N.V. eTheRNA Ethris GmbH GSK PLC Moderna,Inc. Pfizer Inc., Sanofi Stemirna Therapeutics Translate Bio ( now a Sanofi Company)
List of Other Companies Mentioned in the report AGC Biologics Almac Clinical Services Beam Therapeutics BioNet-Asia Boehringer Ingelheim CRISPR Therapeutics Curia Daichi Sankyo Dendron Pharmaceuticals Eurofins Genomics European Society of Gene and Cell Therapy EyeGene Fujifilm Diosynth Biotechnologies Gennova Bio Gritstone Bio Hanmi Pharmaceutical Group Imperial College London Intellia Therapeutics Lonza Precision Nanosystems Providence Therapeutics Regeneron Samsung Biologics Sigma Aldrich ThermoFisher Vinbiocare Biotechnology Walvax Biotechnology Wuxi Apptec
List of Associations Mentioned in the Report Association of British Pharmaceutical Industry (ABPI) Bill & Melinda Gates Foundation Central Drugs Standard Control Organization (CDSCO) Development and Reform Commission (NDRC) European Commission European Medicines Agency (EMA) Food and Drug Administration (US FDA) GAVI ( Global Alliance for Vaccines and immunization) Indian Drug Manufacturer's Association (IDMA) International Society of Pharmaceutical Engineering (IPSE) IVAC ( International Vaccine Access Center) Korea Food and Drug Administration (KFDA) Medicines and Healthcare Products Regulatory Agency (MHRA) Medicines Manufacturing Industry Partnership (MMIP) Ministry of Health (MOH) Ministry of Health, Labour and Welfare (MHLW) National Institute of Allergy and Infections (NIAID) PAHO (Pan American Health Organizations) Pharmaceutical and Medical Devices Agency (PMDA) The Defense Advanced Research Projects(DARPA) United Children Funds (UNICEF) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for mRNA Vaccines & Therapeutics Market Report 2022-2032
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033
The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
